Solrikitug not checked
Uniquity One (UNI) · NSI-8226
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- Tested for
- COPD, Eosinophilic Esophagitis (EoE)
- Main trialPhase 2
- “A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).”In the company’s words, NCT06496620 on ClinicalTrials.gov
- Other names
- NSI-8226
Other drugs for COPD
- TQC3721Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- EnsifentrineMerck & Co. · Nuance Pharma · Phase 3
- HSK39004Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- AstegolimabRoche · Phase 3
- Alpha-1 MPGrifols Therapeutics LLC · Phase 3
- JKN2401Joincare Pharmaceutical Group Industry Co., Ltd · Phase 3
Coming up1
- 30 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 23 Sep 2026 | A Study to Evaluate Solrikitug in Participants With COPD (ZION) | |
| Phase 2Active, not recruiting | 30 Apr 2027 | A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis | |
| Phase 2Completed | 6 Jul 2026 | A Study to Evaluate Solriktug in Adult Participants With Asthma | |
| Phase 1Completed | 2 Feb 2026 | A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026